bioAffinity Technologies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	2.82	11.41	1.36	0.08
Cash & Cash Equivalents	2.82	11.41	1.36	0.08
Cash Growth	-75.28%	738.85%	1537.19%	-
Receivables	0.81	0.01	0	0
Inventory	0.02	0.01	0	0
Other Current Assets	0.32	0.53	0.08	0.03
Total Current Assets	3.97	11.96	1.44	0.12
Property, Plant & Equipment	1.99	0.21	0	0.01
Goodwill and Intangibles	2.24	0	0	0
Other Long-Term Assets	0.02	0.01	0.01	0.02
Total Long-Term Assets	4.25	0.22	0.02	0.03
Total Assets	8.22	12.18	1.45	0.15
Accounts Payable	0.6	0.35	0.23	0.19
Deferred Revenue	0.03	0	0	0
Current Debt	0.46	0.25	11.2	9.95
Other Current Liabilities	1.15	0.54	1.6	0.98
Total Current Liabilities	2.25	1.14	13.04	11.12
Long-Term Debt	1.12	0	0.16	0.05
Total Long-Term Liabilities	1.12	0	0.16	0.05
Total Liabilities	3.37	1.14	13.2	11.17
Total Debt	1.58	0.25	11.36	10.01
Debt Growth	527.08%	-97.78%	13.57%	-
Retained Earnings	-44.6	-36.67	-28.51	-22.19
Shareholders' Equity	4.86	11.04	-15.79	-15.07
Net Cash / Debt	1.24	11.16	-10	-9.92
Net Cash / Debt Growth	-88.86%	-	-	-
Net Cash Per Share	0.14	2.48	-3.74	-3.71
Working Capital	1.72	10.82	-11.6	-11
Book Value Per Share	0.56	2.46	-5.90	-5.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).